Alzheimer Drug (Bapineuzumab) Has No Benefits

New Medications For Alzheimers / The Maher Law Firm / Frank Eidson

The new Alzheimer’s drug Bapineuzumab has not lead to significant improvements. Bapineuzumab – an intravenous Alzheimer’s medication – recently went through a phase 3 trial in patients with mild-to-moderate Alzheimer’s disease whom did not carry the ApoE4 genotype (ApoE4 is thought to increase a person’s chance of developing Alzheimer’s and may worsen symptoms)  announced Pfizer [...]